Literature DB >> 32611637

Associative memory and in vivo brain pathology in asymptomatic presenilin-1 E280A carriers.

Edmarie Guzmán-Vélez1, Jairo Martínez1, Kate Papp1, Ana Baena1, Clara Vila-Castelar1, Arabiye Artola1, Aaron P Schultz1, Yamile Bocanegra1, Justin Sanchez1, Dorene Rentz1, Pierre N Tariot1, Eric M Reiman1, Reisa Sperling1, Keith A Johnson1, Francisco Lopera1, Yakeel T Quiroz2.   

Abstract

OBJECTIVE: To determine whether performance on the Free and Cued Selective Reminding Test (FCSRT) is associated with PET in vivo markers of brain pathology and whether it can distinguish those who will develop dementia later in life due to autosomal-dominant Alzheimer disease (AD) from age-matched controls.
METHODS: Twenty-four cognitively unimpaired Presenilin-1 E280A carriers (mean age 36 years) and 28 noncarriers (mean age 37 years) underwent Pittsburg compound B-PET (amyloid), flortaucipir-PET (tau), and cognitive testing, including the FCSRT (immediate and delayed free and cued recall scores). Linear regressions were used to examine the relationships among FCSRT scores, age, mean cortical amyloid, and regional tau burden.
RESULTS: Free and total recall scores did not differ between cognitively unimpaired mutation carriers and noncarriers. Greater age predicted lower free recall and delayed free and total recall scores in carriers. In cognitively impaired carriers, delayed free recall predicted greater amyloid burden and entorhinal tau, while worse immediate free recall scores predicted greater tau in the inferior temporal and entorhinal cortices. In turn, in all carriers, lower free and total recall scores predicted greater amyloid and regional tau pathology.
CONCLUSIONS: FCSRT scores were associated with in vivo markers of AD-related pathology in cognitively unimpaired individuals genetically determined to develop dementia. Difficulties on free recall, particularly delayed recall, were evident earlier in the disease trajectory, while difficulties on cued recall were seen only as carriers neared the onset of dementia, consistent with the pathologic progression of the disease. Findings suggest that the FCSRT can be a useful measure to track disease progression in AD.
© 2020 American Academy of Neurology.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32611637      PMCID: PMC7538214          DOI: 10.1212/WNL.0000000000010177

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  33 in total

1.  Mild cognitive impairment: clinical characterization and outcome.

Authors:  R C Petersen; G E Smith; S C Waring; R J Ivnik; E G Tangalos; E Kokmen
Journal:  Arch Neurol       Date:  1999-03

2.  Associations between biomarkers and age in the presenilin 1 E280A autosomal dominant Alzheimer disease kindred: a cross-sectional study.

Authors:  Adam S Fleisher; Kewei Chen; Yakeel T Quiroz; Laura J Jakimovich; Madelyn Gutierrez Gomez; Carolyn M Langois; Jessica B S Langbaum; Auttawut Roontiva; Pradeep Thiyyagura; Wendy Lee; Napatkamon Ayutyanont; Liliana Lopez; Sonia Moreno; Claudia Muñoz; Victoria Tirado; Natalia Acosta-Baena; Anne M Fagan; Margarita Giraldo; Gloria Garcia; Matthew J Huentelman; Pierre N Tariot; Francisco Lopera; Eric M Reiman
Journal:  JAMA Neurol       Date:  2015-03       Impact factor: 18.302

3.  Tau and β-Amyloid Are Associated with Medial Temporal Lobe Structure, Function, and Memory Encoding in Normal Aging.

Authors:  Shawn M Marks; Samuel N Lockhart; Suzanne L Baker; William J Jagust
Journal:  J Neurosci       Date:  2017-02-17       Impact factor: 6.167

4.  Neuropsychological measures that detect early impairment and decline in preclinical Alzheimer disease.

Authors:  Suzanne E Schindler; Mateusz S Jasielec; Hua Weng; Jason J Hassenstab; Ellen Grober; Lena M McCue; John C Morris; David M Holtzman; Chengjie Xiong; Anne M Fagan
Journal:  Neurobiol Aging       Date:  2017-04-14       Impact factor: 4.673

5.  Pre-dementia clinical stages in presenilin 1 E280A familial early-onset Alzheimer's disease: a retrospective cohort study.

Authors:  Natalia Acosta-Baena; Diego Sepulveda-Falla; Carlos Mario Lopera-Gómez; Mario César Jaramillo-Elorza; Sonia Moreno; Daniel Camilo Aguirre-Acevedo; Amanda Saldarriaga; Francisco Lopera
Journal:  Lancet Neurol       Date:  2011-02-04       Impact factor: 44.182

6.  Biomarker validation of a cued recall memory deficit in prodromal Alzheimer disease.

Authors:  M Wagner; S Wolf; F M Reischies; M Daerr; S Wolfsgruber; F Jessen; J Popp; W Maier; M Hüll; L Frölich; H Hampel; R Perneczky; O Peters; H Jahn; C Luckhaus; H-J Gertz; J Schröder; J Pantel; P Lewczuk; J Kornhuber; J Wiltfang
Journal:  Neurology       Date:  2012-01-11       Impact factor: 9.910

Review 7.  Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments.

Authors:  Eric M Reiman; Jessica B S Langbaum; Adam S Fleisher; Richard J Caselli; Kewei Chen; Napatkamon Ayutyanont; Yakeel T Quiroz; Kenneth S Kosik; Francisco Lopera; Pierre N Tariot
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

8.  A Three-Factor Structure of Cognitive Functioning Among Unimpaired Carriers and Non-Carriers of Autosomal-Dominant Alzheimer's Disease.

Authors:  Edmarie Guzmán-Vélez; Sehily Jaimes; Daniel C Aguirre-Acevedo; Daniel J Norton; Kathryn V Papp; Rebecca Amariglio; Dorene Rentz; Ana Baena; Eliana Henao; Victoria Tirado; Claudia Muñoz; Margarita Giraldo; Reisa A Sperling; Francisco Lopera; Yakeel T Quiroz
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

9.  The preclinical Alzheimer cognitive composite: measuring amyloid-related decline.

Authors:  Michael C Donohue; Reisa A Sperling; David P Salmon; Dorene M Rentz; Rema Raman; Ronald G Thomas; Michael Weiner; Paul S Aisen
Journal:  JAMA Neurol       Date:  2014-08       Impact factor: 18.302

10.  Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry.

Authors:  Heiko Braak; Irina Alafuzoff; Thomas Arzberger; Hans Kretzschmar; Kelly Del Tredici
Journal:  Acta Neuropathol       Date:  2006-08-12       Impact factor: 17.088

View more
  2 in total

1.  Longitudinal amyloid and tau accumulation in autosomal dominant Alzheimer's disease: findings from the Colombia-Boston (COLBOS) biomarker study.

Authors:  Justin S Sanchez; Bernard J Hanseeuw; Francisco Lopera; Reisa A Sperling; Ana Baena; Yamile Bocanegra; David Aguillon; Edmarie Guzmán-Vélez; Enmanuelle Pardilla-Delgado; Liliana Ramirez-Gomez; Clara Vila-Castelar; Jairo E Martinez; Joshua T Fox-Fuller; Claudia Ramos; Martin Ochoa-Escudero; Sergio Alvarez; Heidi I L Jacobs; Aaron P Schultz; Jennifer R Gatchel; J Alex Becker; Samantha R Katz; Danielle V Mayblyum; Julie C Price; Eric M Reiman; Keith A Johnson; Yakeel T Quiroz
Journal:  Alzheimers Res Ther       Date:  2021-01-15       Impact factor: 6.982

Review 2.  The Multi-Partner Consortium to Expand Dementia Research in Latin America (ReDLat): Driving Multicentric Research and Implementation Science.

Authors:  Agustin Ibanez; Jennifer S Yokoyama; Katherine L Possin; Diana Matallana; Francisco Lopera; Ricardo Nitrini; Leonel T Takada; Nilton Custodio; Ana Luisa Sosa Ortiz; José Alberto Avila-Funes; Maria Isabel Behrens; Andrea Slachevsky; Richard M Myers; J Nicholas Cochran; Luis Ignacio Brusco; Martin A Bruno; Sonia M D Brucki; Stefanie Danielle Pina-Escudero; Maira Okada de Oliveira; Patricio Donnelly Kehoe; Adolfo M Garcia; Juan Felipe Cardona; Hernando Santamaria-Garcia; Sebastian Moguilner; Claudia Duran-Aniotz; Enzo Tagliazucchi; Marcelo Maito; Erika Mariana Longoria Ibarrola; Maritza Pintado-Caipa; Maria Eugenia Godoy; Vera Bakman; Shireen Javandel; Kenneth S Kosik; Victor Valcour; Bruce L Miller
Journal:  Front Neurol       Date:  2021-03-11       Impact factor: 4.003

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.